GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting
- Evidence of biologic activity of GMI-1359 observed in Phase 1b clinical trial interim analysis
- Preclinical data highlight anti-tumor activity in pancreatic cancer model with GMI-1757, a novel galectin-3 antagonist
Details on
Title: “Development of GMI-1359, a Novel Agent Targeting Tumor-microenvironment Cross-talk in Bone Metastatic Breast Cancer”
Presenter:
Session: e-Presentation
Date and Time:
Title: A novel glycomimetic compound (GMI-1757) with dual functional antagonism to E-selectin and galectin-3 attenuates fibrosis, facilitates mononuclear cell infiltration and optimizes anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model
Presenter:
Session: e-Presentation
Date and Time:
About GMI-1757
An innovative dual antagonist of E-selectin and galectin-3, GMI-1757 was described in a poster presented at the 2018 annual meeting of the
About GMI-1359
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow, such as AML and multiple myeloma, or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor affecting about 900 adolescents a year in
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development of the Company’s product candidates, as well as the presentation of data from preclinical studies and clinical trials and the potential benefits and impact of the Company’s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005918/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: